Federated Hermes
RANI icon

Federated Hermes’s Rani Therapeutics RANI Stock Holding History

Federated Hermes’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$587 Buy
+799
New +$1.02K ﹤0.01% 2026

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Federated Hermes's RANI Position: Q1 2026 in Review

Federated Hermes opened a new position in Rani Therapeutics (RANI) in Q1 2026: 799 shares worth $587. The stake represents ﹤0.01% of the portfolio and ranks #2026 among its holdings.

74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Federated Hermes held 799 shares of Rani Therapeutics worth $587 as of Q1 2026.
  • Rani Therapeutics was a new Federated Hermes position in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #2026 holding.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.